ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

MBRX Moleculin Biotech Inc

5,02
0,01 (0,20%)
30 Apr 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Moleculin Biotech Inc MBRX NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,01 0,20% 5,02 22:30:00
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
5,00 4,79 5,2466 5,02 5,01
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
18.4.202414:30PRNUSEuropean Medicines Agency (EMA) Grants Orphan Drug..
10.4.202414:30PRNUSMoleculin Announces Presentation of Positive Data..
28.3.202415:45PRNUSMoleculin to Present at the MedInvest Biotech & Pharma..
27.3.202414:25PRNUSMoleculin to Participate in the Virtual Investor Lunch..
27.3.202414:05PRNUSMoleculin Announces U.S. Patent Issue Notification for..
25.3.202412:30PRNUSMoleculin Announces Positive Interim Data in Annamycin..
22.3.202421:05PRNUSMoleculin Reports Full Year 2023 Financial Results
20.3.202412:30PRNUSMoleculin to Report Full Year 2023 Financial Results on..
20.3.202412:15IHMARKETNEWSJPMorgan boosts dividends, Chipotle unveils 50:1 stock..
19.3.202421:30PRNUSMoleculin Announces Reverse Stock Split
12.3.202414:05PRNUSMoleculin to Present at the 36th Annual ROTH Conference
29.2.202414:30EDGAR2Form 8-K - Current report
22.2.202415:30EDGAR2Form 8-K - Current report
16.2.202423:19EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
15.2.202415:15EDGAR2Form 8-K - Current report
14.2.202422:36EDGAR2Form 8-K - Current report
14.2.202422:33EDGAR2Form 8-K - Current report
13.2.202406:15EDGAR2Form EFFECT - Notice of Effectiveness
02.2.202423:05EDGAR2Form S-1 - General form for registration of securities under..
24.1.202414:50EDGAR2Form 8-K - Current report
24.1.202414:50PRNUSMoleculin Announces 2023 Year-End Annamycin Clinical Trials..
16.1.202423:00EDGAR2Form DEF 14A - Other definitive proxy statements
05.1.202423:15EDGAR2Form PRE 14A - Other preliminary proxy statements
05.1.202423:14EDGAR2Form 8-K - Current report
27.12.202313:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22.12.202323:00EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
21.12.202323:17EDGAR2Form 8-K - Current report
21.12.202303:16PRNUSMoleculin Announces Pricing of $4.5 Million Registered..
18.12.202314:55EDGAR2Form 8-K - Current report
11.12.202314:55EDGAR2Form 8-K - Current report
11.12.202314:50EDGAR2Form 8-K - Current report
11.12.202314:50PRNUSMoleculin Presents Positive Interim Data from Phase 1B/2..
20.11.202315:15EDGAR2Form 8-K - Current report
13.11.202314:30EDGAR2Form 8-K - Current report
13.11.202314:05EDGAR2Form 8-K - Current report
13.11.202314:05PRNUSMoleculin Announces Positive Interim Data in Annamycin..
13.11.202314:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13.11.202314:00EDGAR2Form 8-K - Current report
13.11.202314:00PRNUSMoleculin Reports Third Quarter 2023 Financial Results
07.11.202314:45EDGAR2Form 8-K - Current report
07.11.202314:45PRNUSMoleculin to Report Third Quarter Financial Results on..
06.11.202314:35EDGAR2Form 8-K - Current report
06.11.202314:35PRNUSMoleculin Presents Positive Preliminary Efficacy Findings..
03.11.202321:30EDGAR2Form 8-K - Current report
17.10.202315:00EDGAR2Form 8-K - Current report
11.10.202315:05PRNUSMoleculin to Participate in the Virtual Investor Ask the CEO..
06.10.202323:15EDGAR2Form 8-K - Current report
02.10.202314:40EDGAR2Form 8-K - Current report
02.10.202314:40PRNUSMoleculin Doses First Subjects in Phase 2 Portion of..
21.9.202314:50EDGAR2Form 8-K - Current report

Kürzlich von Ihnen besucht

Delayed Upgrade Clock